Home>>Signaling Pathways>> Metabolism>> PPAR>>GW1929

GW1929 Sale

(Synonyms: N-(2-苯甲酰基苯基)-O-[2-(甲基-2-吡啶基氨基)乙基]-L-酪氨酸,GW 1929;GW-1929) 目录号 : GC11423

A non-thiazolidinedione activator of PPARγ

GW1929 Chemical Structure

Cas No.:196808-24-9

规格 价格 库存 购买数量
10mg
¥1,485.00
现货
50mg
¥5,490.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Kinase experiment:

Ligand binding to bacterially expressed ligand binding domain (LBD) of hPPAR-γ is determined by scintillation proximity assay (SPA). The assay measures the ability of putative ligands to displace receptor bound [3H]BRL 49653. Assays are conducted in 96-well plates. Wells contained varying concentrations of GW1929 or troglitazone; streptavidin-modified SPA beads to which biotinylates PPAR-γ LBD is prebound; and 10 nM of the specific radioligand [3H]BRL 49653 in a volume of 100 μL. The amount of nonspecific binding, as assessed by control wells that contained 50 μM of the corresponding unlabeled ligand, is subtracted from each data point. For each compound tested, plots of ligand concentration versus counts/min of radioligand bound are constructed, and apparent Ki values are estimated from a nonlinear least squares fit of the data, assuming simple competitive binding. The results are expressed as pKi, where pKi = -log10(KI)[1].

Cell experiment:

For the experiments, the cells are plated in 96-well plates at a density 2 × 105 cells per cm2 and cultured in the presence of TBBPA, in a concentrations range from 1 nM to 100 μM TBBPA. TBBPA is dissolved in DMSO, resulting in a final vehicle concentration of 0.1 % (v/v). Control (no vehicle) and DMSO-treated wells are included in the experimental design to determine the effect of DMSO. To study whether PPAR-γ is involved in the neurotoxic effect of TBBPA, cells are co-treated with 10 μM TBBPA and 10 μM GW1929 or GW9662. After 6 or 24 h of culture, 100 μL medium is collected for the LDH analysis, and the cells are collected and frozen at −70°C for the caspase-3 activity measurements[2].

Animal experiment:

Animals are housed at 72°F and 50% relative humidity with a 12-h light and dark cycle, and fed Formulab Diet 5008. Age- (60-day) and glucose-matched male Zucker diabetic fatty rats are gavaged twice daily for 14 days with vehicle (0.05 M N-methylglucamine), GW1929 (0.5, 1.0, or 5.0 mg/kg), or troglitazone (as the milled extrudate, in a suspension in methylcellulose, 50, 150, and 500 mg/kg). Another group of animals receives a mixture of Humulin N and Humulin R by subcutaneous injection twice daily. On days 7 and 14 of dosing, nonfasted measurements of glucose, lactate, insuline, total cholesterol, TGs, F FAs, and hematocrit are obtained. On day 14 of dosing, samples for serum drug levels (2-h postdose) and glycosylated hemoglobin measurements are also collected. In addition, once weekly, three animals from each group are placed in metabolic chambers for 48 h for quantitation of 24-h food and water consumption. Body weights are recorded throughout the study. At the conclusion of the study, perfused pancreas experiments are performed on 12 animals (n = 4 per group) that have received either GW1929 (1 and 5 mg/kg) or vehicle, to directly evaluate the effects of treatment on basal and glucose-stimulated insuline secretion. The remaining animals are killed, and their pancreases are processed for immunocytochemistry[1].

References:

[1]. Brown KK, et al. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes. 1999 Jul;48(7):1415-24.
[2]. Wojtowicz AK, et al. PPAR-γ agonist GW1929 but not antagonist GW9662 reduces TBBPA-induced neurotoxicity in primary neocortical cells. Neurotox Res. 2014 Apr;25(3):311-22.

产品描述

IC50: 5.0 μM

GW1929 is a nonthiazolidinedione PPARγ agonist. Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors with three isoforms: PPARα, PPARγ, and PPARβ/δ. Among these, PPARγ is highly expressed in various brain regions. A growing evidences have suggested that PPARγ play a key role in pathogenesis of cerebral IR injury

In vitro: GW1929 was tested on currents through L-type voltage-dependent calcium channels (VDCC) in freshly isolated smooth muscle cells. Using Ba2+ as the charge carrier through VDCC, the IC50s for GW1929 and pioglitazone were determined to be 5.0 +/- 0.7 and 10.0 +/- 0.8 μM, respectively. GW1929 and pioglitazone were both effective on inhibiting VDCC and relaxing pressurized arteries, indicating the vasodilation of resistance arteries might be explained by the inhibition of calcium entry through VDCC [1].

In vivo: GW1929 treatment attenuated the neurological damage in focal cerebral IR injury significantly. In addition, the neuroprotective effects of GW1929 were found to be associated with significant reduction in the levels of MMP-9, COX-2, iNOS, TNFα and IL-6. Neuroprotective effects of GW1929 related with significant reduction in TUNEL positive cells in IR challenged brain [2].

Clinical trial: N/A

References:
[1] Heppner TJ,Bonev AD,Eckman DM,Gomez MF,Petkov GV,Nelson MT. Novel PPARgamma agonists GI 262570, GW 7845, GW 1929, and pioglitazone decrease calcium channel function and myogenic tone in rat mesenteric arteries. Pharmacology.2005 Jan;73(1):15-22.
[2] Kaundal RK,Sharma SS.  Ameliorative effects of GW1929, a nonthiazolidinedione PPARγ agonist, on inflammation and apoptosis in focal cerebral ischemic-reperfusion injury. Curr Neurovasc Res.2011 Aug 1;8(3):236-45.

Chemical Properties

Cas No. 196808-24-9 SDF
别名 N-(2-苯甲酰基苯基)-O-[2-(甲基-2-吡啶基氨基)乙基]-L-酪氨酸,GW 1929;GW-1929
化学名 2-((2-benzoylphenyl)amino)-3-(4-(2-(methyl(pyridin-2-yl)amino)ethoxy)phenyl)propanoic acid
Canonical SMILES CN(C1=CC=CC=N1)CCOC2=CC=C(CC(NC3=CC=CC=C3C(C4=CC=CC=C4)=O)C(O)=O)C=C2
分子式 C30H29N3O4 分子量 495.57
溶解度 ≥ 35 mg/mL in DMSO 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.0179 mL 10.0894 mL 20.1788 mL
5 mM 0.4036 mL 2.0179 mL 4.0358 mL
10 mM 0.2018 mL 1.0089 mL 2.0179 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置